PharmaKure granted MHRA Clinical Trial Authorisation (CTA) for PK051 for the treatment of mild cognitive impairment due to Alzheimer’s Disease

Clinical Trial Authorisation application granted for combined drug PK051 targeting amyloid deposits associated with Alzheimer’s Disease.

Cellular Origins, Fresenius Kabi sign development agreement for scalable automation of cell and gene therapy manufacturing

Cellular Origins and Fresenius Kabi, an operating company of Fresenius, announce today they have signed a development agreement that leverages each company’s expertise in cell

October 16, 2024

Nearly 2,000 Pharmaceutical Plants Are Overdue for FDA Checks After COVID Delays

Federal regulators responsible for the safety of the U.S. drug supply are still struggling to get back to where they were in 2019, before the

September 6, 2024

Opinion | I Can’t Guarantee Your Next Round of Chemo

Teplinsky is a breast and gynecologic medical oncologist. “We are running low on cisplatin.” “The e-mail came. We are out of carboplatin.” “How do I

July 6, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.